Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

North China Pharmaceutical Co Ltd Revises FY 2012 Net Profit Outlook


Wednesday, 30 Jan 2013 07:00pm EST 

North China Pharmaceutical Co Ltd announced that it expects a profit for fiscal year (FY) 2012 but to decrease by above 50%, compared to the net profit of FY 2011 (RMB 124,769,893.42). The Company previously announced that it expected a loss for FY 2012. The Company cited the received compensation as the main reason for the revision. 

Company Quote

6.69
0.07 +1.06%
23 Oct 2014